SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis
SGLT2-Is are associated with improved cardiovascular outcomes in patients with AMI, including reductions in recurrent AMI, all-cause hospitalizations and mortality, and cardiac arrest. These findings emphasize the need for prospective clinical trials involving patients with AMI and other cardiovascular comorbidities, regardless of LVEF, to confirm these results.
Authors
- Kwan Lee (ORCID: https://orcid.org/0000-0001-6302-9925)
- Hoang Nhat Pham (ORCID: https://orcid.org/0000-0001-8412-0082)
- Min Choon Tan (ORCID: https://orcid.org/0000-0002-7682-8934)
- George Bcharah (ORCID: https://orcid.org/0009-0009-9296-2824)
- Mahmoud Hassan Abdelnabi (ORCID: https://orcid.org/0000-0001-8016-9049)
- Ramzi Ibrahim (ORCID: https://orcid.org/0000-0003-0124-9513)
- Juan Farina (ORCID: https://orcid.org/0000-0002-5824-8485)
- Mohamed Allam (ORCID: https://orcid.org/0000-0002-7687-9344)
- Chadi Ayoub (ORCID: https://orcid.org/0000-0001-5877-7478)
- Gerald Lim
- Reza Arsanjani
- Timothy Barry
- Xuan Ci Mee (ORCID: https://orcid.org/0009-0005-3878-5506)
Institutions
- University of Arizona (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1093/ehjcvp/pvaf026
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47